Compare SIEB & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | BDSX |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 162.8M |
| IPO Year | 1996 | 2020 |
| Metric | SIEB | BDSX |
|---|---|---|
| Price | $1.83 | $14.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 16.6K | ★ 73.4K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $94,202,000.00 | $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | 12.28 | ★ 24.08 |
| 52 Week Low | $1.68 | $0.25 |
| 52 Week High | $5.53 | $20.21 |
| Indicator | SIEB | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 52.56 |
| Support Level | $1.68 | $13.41 |
| Resistance Level | $1.97 | $16.26 |
| Average True Range (ATR) | 0.08 | 1.11 |
| MACD | 0.01 | 0.32 |
| Stochastic Oscillator | 25.08 | 66.04 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.